Biotech Updates

Arcadia Receives Fund to Continue Research on Wheat with Reduced Celiac Disease Potential

February 19, 2010

The United States National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the American Recovery and Reinvestment Act (ARRA) has awarded biotech company Arcadia Biosciences and the University of Washington a USD 855,000 grant to help fund Phase II development of wheat varieties with reduced celiac disease-causing proteins.

Celiac disease is a digestive disorder that, in sensitive individuals, results from a toxic reaction to certain proteins found in specific grains, including wheat. This reaction in celiac sufferers causes damage to the small intestine and inhibits proper food absorption. Approximately 1 percent of Americans have the disease, and the incidence is even higher in some northern European countries.

Arcadia expects to complete Phase II research in mid-2011. The company has not released commercialization timeline for the wheat varieties.

Read for more information.